The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

Thu, 14th Mar 2024 07:52

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

At 1230 GMT, there is the weekly initial jobless claims reading, as well as producer price and retail sales data.

Swissquote analyst Ipek Ozkardeskaya commented: "Retail sales are expected to have rebounded following a relatively weak read in January, while producer prices are expected to have risen in February, fuelled by higher energy prices. Normally, I would expect higher-than-expected retail sales and higher-than-expected PPI data to temper the Fed rate cut bets, back a further rise in US yields and the dollar, and trigger a downside correction in the US stock markets."

The producer price index numbers are expected to show the pace of year-on-year US producer price growth picked up to 1.1% on in February, according to FXStreet cited consensus, from 0.9% in January.

Retail sales are expected to have risen 0.8% on month in February, following a 0.8% fall in January from December.

In early UK corporate news, AstraZeneca announced a USD1.05 billion deal to boost its rare disease pipeline, Halma backed its outlook and Trainline said its revenue growth was better-than-forecast.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up just 1.0 points at 7,773.17

----------

Hang Seng: down 0.9% at 16,934.40

Nikkei 225: up 0.3% at 38,794.36

S&P/ASX 200: closed down 0.2% at 7,713.60

----------

DJIA: closed up 37.83 points, 0.1%, at 39,043.32

S&P 500: closed down 0.2% at 5,165.31

Nasdaq Composite: closed down 0.5% at 16,177.77

----------

EUR: lower at USD1.0934 (USD1.0945)

GBP: flat at USD1.2798 (USD1.2798)

USD: up at JPY147.92 (JPY147.70)

GOLD: down at USD2,167.96 per ounce (USD2,173.55)

(Brent): up at USD84.08 a barrel (USD83.50)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

11:30 GMT Ireland CPI

12:30 GMT US initial jobless claims

12:30 GMT US PPI

12:30 GMT US retail sales

----------

A "solid rise" in sellers in the UK putting their homes on the market was seen in February, with the strongest upswing recorded since autumn 2020, according to surveyors. A net balance of 21% of property professionals reported new instructions to sell rising rather than falling, marking the strongest reading since October 2020, the Royal Institution of Chartered Surveyors said. This finding is in contrast to the continuously negative picture cited throughout 2023, Rics added. On average, estate agents' branches had 42 properties, the highest number recorded by Rics since February 2021, with those surveyed noting an increase in market appraisals during the month, compared with the same period last year. Across the UK, new buyer inquiries grew for the second month in a row, with a net balance of 6% of professionals reporting a rise rather than a fall.

----------

The UK's defence secretary has called for military spending to be increased to 3% of gross domestic product in a debate about the funding of Britain's armed forces. Speaking on a visit to Poland, Grant Shapps called for the inclusion of the 3% target in the Conservatives' election manifesto, saying: "I want a bigger budget." He also called for an overhaul of recruitment, including an end to certain medical requirements and a lifting of the ban on soldiers growing beards, the Daily Mail reported. Shapps said: "I have coined the phrase 'moving from post-war to pre-war'. We have to be much better prepared. "Defence is the best way to protect ourselves against a military conflict – you have to show your adversaries – so I am clearly in favour (of a 3% target). We live in a more dangerous world, we've got Putin on the front line making gains." Research by the Royal United Services Institute in 2022 suggested that increasing defence spending to 3% of GDP by 2030, as suggested by Liz Truss's government, would require GBP157 billion in additional spending over the following eight years.

----------

BROKER RATING CHANGES

----------

JPMorgan places Legal & General on 'positive catalyst watch'

----------

JPMorgan reinitiates LondonMetric with 'overweight' - price target 230 pence

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm AstraZeneca said it has struck a deal to acquire Amolyt Pharma, strengthening its late-stage rare disease pipeline. Astra will pay up to USD1.05 billion to acquire the developer of endocrine disease treatments. The endocrine system includes major glands in the body such as the thyroid and the hypothalamus. Astra said: "The proposed acquisition will bolster the Alexion, AstraZeneca rare disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. Additionally, Alexion is looking forward to welcoming talent from Amolyt Pharma." Astra will pay USD800 million at closing, and the deal also includes a possible USD250 million milestone payment. Hypoparathyroidism is when the parathyroid glands produce too little of the parathyroid hormone. It can cause muscle crumps, facial twitches and rough skin.

----------

Halma left its full-year outlook unchanged, as the safety equipment firm hailed the "further progress" it made in the second half of its financial year. For the year to March 31, it expects adjusted pretax profit to be in line with consensus of GBP388.5 million, which would be a 7.5% rise from GBP361.3 million in the year prior. Halma said: "We have delivered strong constant currency revenue growth in the year to date, comprising good momentum on an organic constant currency basis and a continued healthy contribution from recent acquisitions." Halma said order intake "remains ahead of the comparable period last year". The firm also noted that sterling appreciation has been a currency translation headwind, however.

----------

COMPANIES - FTSE 250

----------

Lender OSB Group said its net interest income and profit weakened in 2023, though it maintained its final dividend and announced a new GBP50 million share buyback programme. Pretax profit was 30% lower at GBP374.3 million in 2023, from GBP531.5 million in 2022. Total income fell 15% to GBP658.1 million from GBP775.4 million. Hurting its total income, it reported a GBP4.4 million fair value loss on financial instruments, contrasting with a GBP58.9 million gain in 2022. Net interest income alone fell 7.2% to GBP658.6 million in 2023. OSB, which stands for OneSavings Bank, in July warned its results would be hurt by customers acting more quickly than expected to refinance their mortgages at favourable rates. OSB declared a 21.8 pence per share final dividend, unmoved from the year prior. Its total dividend was boosted by 4.9% to 32.0p from 30.5p. "We have also announced a new GBP50 million share buyback over the next six months and the board will consider additional shareholder returns later in the year," it added. Further, Chief Financial Officer April Talintyre will not be seeking re-election at the annual general meeting on May 9 and will also retire as executive director that day. Deputy CFO Victoria Hyde will serve as acting CFO until the company finds a new permanent CFO.

----------

Rail ticket selling platform Trainline said it "outperformed expectations" in its recently-ended financial year. It said revenue in the year to February 29 rose 21% to GBP397 million from GBP327 million. It had guided for a rise between 15% and 20%. Net ticket sales were 22% higher at GBP5.30 billion, at the top end of its growth outlook range. Chief Executive Jody Ford said: "Trainline is a home-grown British tech success that has scaled beyond domestic borders to become Europe's most downloaded rail app. We outperformed expectations this year, growing strongly in the UK and across the continent, with International Consumer net ticket sales of more than GBP1 billion."

----------

OTHER COMPANIES

----------

Food delivery firm Deliveroo hailed a "good financial performance" in 2023, and said it expects to be free cash flow in 2024. For 2023, Deliveroo reported a GBP10.9 million pretax loss, narrowing from GBP230.6 million in 2022. It achieved adjusted earnings before interest, tax, depreciation and amortisation of GBP85.4 million, however, swinging from a loss of GBP45.0 million. Revenue rose 2.8% to GBP2.03 billion from GBP1.97 billion. Chief Executive Will Shu said: "2023 was a good year for Deliveroo and I am proud of what we have delivered financially, operationally and for our consumers. Our focus on service and value for money continues to build consumer trust, which are fundamental to unlocking future growth in this industry. Alongside this, our restaurant and grocery businesses are performing well, we launched our retail offering, Deliveroo Shopping, and we are scaling our advertising business. Building on the strong progress we made in 2023, I'm excited about the further opportunities ahead." For 2024, it expects an adjusted Ebitda in the range of GBP110 million to GBP130 million. It predicts it will be free cash flow positive this year, after reducing its outflow to GBP38 million in 2023, from GBP243 million in 2022.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
Today 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
Today 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.